Abstract
Over the past 25 years, more than 120 drugs have been studied for the treatment of obesity. Orlistat is the only drug approved in the United States and Italy for the long-term therapy. The other drugs studied for a long-term treatment, sibutramine and rimonabant, were withdrawn from market for safety problems [1, 2].
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Notes
- 1.
Sibutramine was withdrawn in Europe by EMA in January 2010, after SCOUT study showing a higher number of nonfatal cardiovascular and cerebrovascular events in patients affected by cardiovascular disease and diabetes and, thus, contraindicated for the use of this drug.
- 2.
A relevant question with drug therapy is to decide whether such therapy must be continuous or intermittent. In the few studies undertaken to clarify this matter and conducted according to the criteria required by the FDA, the intermittent therapy has found to provide results substantially comparable to the long-lasting therapy.
- 3.
See footnote 2.
References
EMA/808179/2009, EMA/H/A-107/1256 del 21/01/2010
EMEA/39457/2009 del 30/01/2009
Kaya A et al (2004) Efficacy of sibutramine, orlistat and combination therapy on short-term weight management in obese patients. Biomed Pharmacother 58:582–587
Douketis JD et al (2007) Systematic review of long-term weight loss studies in obese adults: clinical significance and applicability to clinical practice. Int J Obes (Lond) 31:1554–1559
European Medicines Agency. European Medicines Agency starts review of orlistat-containing medicines. http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2011/09/WC500112798.pdf
Zhi J et al (1994) Retrospective population-based analysis of the dose-response (fecal fat excretion) relationship of orlistat in normal and obese volunteers. Clin Pharmacol Ther 56:82–85
Li Z et al (2005) Meta-analysis: pharmacologic treatment of obesity. Ann Intern Med 142:532–546
Hollander PA et al (1998) Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study. Diabetes Care 21:1288–1294
Davidson MH et al (1999) Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA 281:235–242
Fidler MC, Sanchez M, Raether B et al (2011) A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial. J Clin Endocrinol Metab 96:3067–3077
Smith SR, Weissman NJ, Anderson CM et al (2010) Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med 363:245–256
O’Neil PM, Smith SR, Weissman NJ et al (2012) Randomized placebo controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study. Obesity 20:1426–1436
Garvey WT, Ryan DH, Look M et al (2012) Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr 95:297–308
Gadde KM, Allison DB, Ryan DH et al (2011) Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet 377:1341–1352
Allison DB, Gadde KM, Garvey WT et al (2012) Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obesity (Silver Spring) 20:330–342
Astrup A, Carraro R, Finer N et al (2012) Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. Int J Obes (Lond) 36:843–854
Saxenda Vs. Liraglutide 3.0 mg label. http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206321Orig1s000lbl.pdf. Accessed 7 July 2015
Brunton L, Chabner BA, Knollman B (2011) Goodman and Gilman’s the pharmacological basis of therapeutics, 12th edn. McGraw Hill Education, New York, 1808 p
Ornellas T, Chavez B (2011) Naltrexone SR/bupropion SR (Contrave). Pharmacol Ther 36(5):255–262
Greenway FL, Fujioka K, Plodkonski RA, et al; COR I Study Group (2010) Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 376:595–605
Takeda Pharmaceuticals America, Inc. Contrave (naltrexone HCl and bupropion Hcl) Extended-release tablets [package insert revised 9/2014] (2014) Orexigen Therapeutics, La Jolla
Mysimba summary of product characteristics (2015) http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003687/WC500185580.pdf. Accessed 26 May 2015
Hawkes N (2014) Approval of antiobesity drug is “major regression for patients’ safety”, says health watchdog. BMJ 349:g7805
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Nisoli, E., Muratori, F. (2016). Pharmacological Management. In: Sbraccia, P., Nisoli, E., Vettor, R. (eds) Clinical Management of Overweight and Obesity. Springer, Cham. https://doi.org/10.1007/978-3-319-24532-4_5
Download citation
DOI: https://doi.org/10.1007/978-3-319-24532-4_5
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-24530-0
Online ISBN: 978-3-319-24532-4
eBook Packages: MedicineMedicine (R0)